Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Definite MS diagnosis according to McDonald's criteria;~* Relapsing clinical course, with or without progression;~* Expanded Disability Status Scale \[EDSS\] less or equal to 5.5 (ambulatory);~* Stable dose of IFN-β for at least 26 weeks prior to the screening visit;~* No onset of MS relapse in the preceding 60 days prior to randomization;~* Clinically stable for 4 weeks prior to randomization.~Exclusion Criteria:~* Other chronic disease of the immune system, liver function impairment or chronic pancreatic disease;~* Pregnant or nursing woman;~* Alcohol or drug abuse;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Human immunodeficiency virus \[HIV\] positive status;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
- Teriflunomide 14 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
- Placebo + IFN-β (Type: PLACEBO_COMPARATOR): Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).